Immunome Inc.
Immunome Inc. is a biotechnology company committed to developing first-in-class and best-in-class targeted oncology therapies designed to improve outcomes for cancer patients. The company operates as a clinical-stage biopharmaceutical enterprise with expertise in the discovery, design, development, manufacturing, and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Immunome Inc. does
In the company’s own words
Immunome Inc. is a biotechnology company committed to developing first-in-class and best-in-class targeted oncology therapies designed to improve outcomes for cancer patients. The company operates as a clinical-stage biopharmaceutical enterprise with expertise in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. More information about the company is available at www.immunome.com.
The company's pipeline includes three clinical-stage assets and three preclinical assets. Varegacestat, an oral gamma secretase inhibitor acquired from Ayala Pharmaceuticals, is under evaluation for the treatment of desmoid tumors and achieved positive Phase 3 RINGSIDE trial results in December 2025, with an anticipated new drug application submission planned for the second quarter of 2026. IM-1021 is a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate currently in Phase 1 trials, with observed objective responses in B-cell lymphoma patients. IM-3050 is a fibroblast activation protein-targeted radioligand therapy that received investigational new drug clearance in April 2025. The three preclinical assets—IM-1617, IM-1340, and IM-3050—are solid tumor antibody-drug conjugates with anticipated 2026 investigational new drug submissions.
A cornerstone of Immunome's strategy is HC74, a proprietary topoisomerase 1 inhibitor payload designed to address limitations of existing payloads by reducing efflux potential and increasing bystander activity. The company's discovery approach focuses on designing antibody-drug conjugates against novel or underexplored targets rather than pursuing the small number of highly prevalent targets that dominate the field. Through extensive screening of over 1,000 targets, the company has identified more than 40 targets evaluated in vitro and more than 15 targets evaluated in vivo.
Immunome was formed through strategic acquisitions and licensing agreements, including the acquisition of varegacestat and related assets from Ayala Pharmaceuticals in March 2024 and the acquisition of ROR1 antibody-drug conjugate assets from Zentalis Pharmaceuticals in October 2024. The company's leadership team comprises executives with prior experience in the design, development, and commercialization of cutting-edge targeted cancer therapies, including the first antibody-drug conjugates commercialized for Hodgkin and T-cell lymphoma, urothelial cancer, and cervical cancer.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOTHELL, WA
- Fiscal year end
- December
- CIK
- 1472012
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Immunome Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Immunome Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Immunome Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Immunome Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Immunome Inc.'s last four quarterly filings that the numbers alone won't show?”